Administrative Supplement to CGRP's effect on hearing and balance in a mouse model of migraine

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

  • Research Location

    United States of America, Americas
  • Lead Research Institution

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details


  • Broad Policy Alignment


  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable


The purpose of this COVID-19 research supplement is to critically evaluate if a calcitonin gene-relatedpeptide (CGRP) receptor antagonist can mitigate both neuroinflammatory and hyper-immune responses toSARS-CoV-2 infection. In December 2019, the coronavirus disease (COVID-19) caused by severe acuterespiratory syndrome CoV-2 (SARS-CoV-2) was identified. There are now over ~5.5 million confirmed casesworldwide (1.6 million US), and 345,000 deaths (~100,000 US). COVID-19 causes a respiratory illness like theflu with symptoms such as fever, cough, loss of smell, fatigue, sputum production, shortness of breath, sorethroat, headache, chills, and nausea or vomiting. Approximately 80% of people have mild disease andrecover. However, in those remaining 20%, COVID-19 is severe and there is evidence that progression to themost serious type of COVID-19 illness is related to a hyper-immune response (ie, cytokine storm). Currently,there are no effective vaccines or treatments available for COVID-19. In this supplement we will test the abilityof CGRP-receptor antagonists to inhibit the neuroimmune consequences of SARS-CoV-2 infection, usingtemperature and nausea as an indicator of SARS-CoV2 infection, as we are doing in our parent grant toassess migraine nausea pain. A humanized mouse model has been developed for studying SARS-CoV2,where mice express the human angiotensin-converting enzyme 2 (hACE2), enabling us to model Covid-19 inthe mouse. The FDA has recently approved Biohaven Pharmaceuticals to proceed to a phase 2 clinical trial ofits CGRP-receptor antagonist (vazegepant; currently in phase 3 trials for migraine) to treat patients with severeCOVID-19, suggesting that the neuroinflammatory reaction that is initiated by CGRP in response to SARS-CoV2 could be a therapeutic target for treating severe Covid-19, and that the non-invasive readouts ofneuroinflammation that we are developing could be used to rapidly identify at risk patients. Our hypothesis isthat mild to severe COVID-19 symptoms will occur in the transgenic hACE2 mouse that has been infected withSARS-CoV-2, and that a CGRP receptor antagonist will mitigate these symptoms. The specific aims are totest the following hypotheses that transgenic mice and non-carrier littermates infected with SARS-CoV-2 willexhibit: aim 1) mild severe symptoms based on viral load, and if these symptoms are less severe when treatedwith a CGRP-receptor antagonist; and aim 2) reduced fever and nausea-like pain when treated with a CGRP-receptor antagonist. Information gained from these studies will provide a direct assessment of whether aCGRP-receptor antagonist can mitigate both mild and severe symptoms associated with SARS-CoV-2infection. This proposal also impacts the development of robust preclinical in vivo assays of COVID-19symptoms, paving the way to develop and test future therapeutics for COVID-19.